BRAF and neoplasm: The median age of melanoma patients (n = 101) receiving non-adjuvant, first-line systemic anti-PD-1-based therapy was 68 years [59–77]; 63% were men, and 27% of the tumours had an oncogenic mutation in the BRAF gene.